- Home
- ZLAB vs PVLA Comparison
ZLAB vs PVLA Comparison
Compare ZLAB & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | PVLA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | China | United States |
| Employees | N/A | 14 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZLAB | PVLA |
|---|---|---|
| Price | $18.60 | $113.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $49.60 | ★ $161.13 |
| AVG Volume (30 Days) | ★ 543.3K | 334.8K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $460,156,000.00 | N/A |
| Revenue This Year | $14.46 | N/A |
| Revenue Next Year | $29.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $18.23 |
| 52 Week High | $44.34 | $151.18 |
Technical Indicators
Market Signals| Indicator | ZLAB | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 46.72 | 47.20 |
| Support Level | $17.03 | $85.53 |
| Resistance Level | $19.71 | $147.47 |
| Average True Range (ATR) | 0.68 | 8.64 |
| MACD | -0.08 | -3.58 |
| Stochastic Oscillator | 57.03 | 10.93 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.